About Human Genome Sciences (NASDAQ:HGSI)
Human Genome Sciences, Inc. (HGS) is a biopharmaceutical company. The Company's products include BENLYSTA (belimumab) for systemic lupus erythematosus (SLE) and raxibacumab for inhalation anthrax. HGS continues to deliver raxibacumab to the United States Strategic National Stockpile (SNS) for emergency use in treating inhalation anthrax. In addition to the Company's internal pipeline, it has financial rights to two drugs that GlaxoSmithKline (GSK) has advanced to late-stage development. These include darapladib and albiglutide. A randomized Phase 2 trial is evaluating mapatumumab in combination with Nexavar (sorafenib) for the treatment of advanced hepatocellular cancer. The Company manufactures multiple protein and antibody drugs for use in research, clinical and commercial activities. It produces and purifies these protein and antibody drugs in three process development and manufacturing facilities. In August 2012, GlaxoSmithKline plc acquired HGS.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:HGSI
CUSIPN/A
Phone+1-301-3098504
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Human Genome Sciences (NASDAQ:HGSI) Frequently Asked Questions
What is Human Genome Sciences' stock symbol?
Human Genome Sciences trades on the NASDAQ under the ticker symbol "HGSI."
Has Human Genome Sciences been receiving favorable news coverage?
Media stories about HGSI stock have trended somewhat positive on Tuesday, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Human Genome Sciences earned a coverage optimism score of 0.13 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 49.30 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Human Genome Sciences?
Shares of HGSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Human Genome Sciences?
Human Genome Sciences' mailing address is 14200 Shady Grove Rd, ROCKVILLE, MD 20850-7464, United States. The biopharmaceutical company can be reached via phone at +1-301-3098504.
MarketBeat Community Rating for Human Genome Sciences (HGSI)
MarketBeat's community ratings are surveys of what our community members think about Human Genome Sciences and other stocks. Vote "Outperform" if you believe HGSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HGSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Human Genome Sciences (NASDAQ:HGSI) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
(Data available from 4/24/2016 forward)
Human Genome Sciences (NASDAQ:HGSI) Earnings History and Estimates Chart
Human Genome Sciences (NASDAQ HGSI) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/26/2012 | | ($0.37) | ($0.46) | | | View | N/A |  |
| 4/24/2012 | Q1 2012 | ($0.40) | ($0.47) | | | View | N/A | |
| 2/27/2012 | Q4 2011 | ($0.42) | ($0.41) | | | View | N/A | |
| 10/25/2011 | | ($0.38) | ($0.45) | | | View | N/A | |
| 7/21/2011 | | ($0.41) | ($0.42) | | | View | N/A | |
| 4/28/2011 | | ($0.48) | ($0.69) | | | View | N/A | |
| 2/24/2011 | | ($0.38) | ($0.46) | | | View | N/A | |
| 10/27/2010 | Q3 2010 | ($0.36) | ($0.22) | | | View | N/A | |
| 7/22/2010 | Q2 2010 | ($0.26) | ($0.30) | | | View | N/A | |
| 4/29/2010 | Q1 2010 | ($0.20) | ($0.26) | | | View | N/A | |
| 3/2/2010 | Q4 2009 | ($0.09) | ($0.06) | | | View | N/A | |
| 10/29/2009 | Q3 2009 | ($0.28) | ($0.32) | | | View | N/A | |
| 7/22/2009 | Q2 2009 | ($0.35) | ($0.48) | | | View | N/A | |
| 4/29/2009 | Q1 2009 | $0.49 | $0.56 | | | View | N/A | |
| 2/26/2009 | Q4 2008 | ($0.48) | ($0.41) | | | View | N/A | |
| 11/6/2008 | Q3 2008 | ($0.50) | ($0.46) | | | View | N/A | |
| 7/30/2008 | Q2 2008 | ($0.55) | ($0.55) | | | View | N/A | |
| 5/5/2008 | Q1 2008 | ($0.25) | ($0.35) | | | View | N/A | |
| 2/25/2008 | Q4 2007 | ($0.49) | ($0.69) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Human Genome Sciences (NASDAQ:HGSI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Human Genome Sciences (NASDAQ HGSI) Insider Trading and Institutional Ownership History
Human Genome Sciences (NASDAQ HGSI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Human Genome Sciences (NASDAQ HGSI) News Headlines
| Source: |
|
No headlines for this company have been tracked by MarketBeat.com
Human Genome Sciences (NASDAQ:HGSI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Human Genome Sciences (NASDAQ:HGSI) Income Statement, Balance Sheet and Cash Flow Statement
Human Genome Sciences (NASDAQ HGSI) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
